重组人干扰素α 1b治疗轮状病毒性肠炎的疗效观察.docxVIP

重组人干扰素α 1b治疗轮状病毒性肠炎的疗效观察 重组人干扰素α-1b治疗轮状病毒性肠炎的疗效观察 　　【摘要】目的观察重组人干扰素α-1b治疗轮状病毒性肠炎中的临床疗效。方法120例轮状病毒性肠炎患儿，随机分为治疗组与对照组，各60例。对照组患儿采用双歧杆菌三联活菌、蒙脱石散及补液等综合治疗，治疗组在对照组基础上加用重组人干扰素α-1b注射液治疗。比较两组患者退热及止泻时间、临床疗效、抗原转阴情况、随访结果、不良反应发生情况。结果治疗组患儿退热、止泻时间分别为（1.78±0.69）、（3.28±1.32）d，均明显短于对照组的（2.84±1.35）、（4.58±1.28）d，差异有统计学意义（p0.05）。治疗组患儿总有效率95.00%及抗原转阴率86.67%显著高于对照组的68.33%、48.33%，差异有统计学意义（p0.05）。两组均未见明显不良反应发生。结论重组人干扰素α-1b治疗轮状病毒性肠炎，可明显缩短疗程，迅速改善症状，且未出现明显不良反应，值得临床推廣应用。 　　【关键词】干扰素α-1b;轮状病毒;肠炎;双歧杆菌三联活菌;蒙脱石散 　　doi：10.14163/ki.11-5547/r.2019.01.048 　　【abstract】objectivetoobservetheclinicalefficacyofrecombinanthumaninterferonα-1bonthetreatmentofrotavirusenteritis.methodsatotalof120rotavirusenteritischildrenwererandomlydividedintotreatmentgroupandcontrolgroup，with60casesineachgroup.thecontrolgroupreceivedcomprehensivetreatmentofbifidobacteriumtriplelivebacteria，montmorillonitepowderandfluidreplacement，andthetreatmentgroupreceivedrecombinanthumaninterferonα-1parisonweremadeonantipyreticandantidiarrhealtime，clinicalefficacy，antigennegative，follow-upresults，occurrenceofadversereactionsbetweenthetwogroups.resultsthetreatmentgrouphadobviouslyshorterantipyreticandantidiarrhealtimerespectivelyas（1.78±0.69）and（3.28±1.32）dthan（2.84±1.35）and（4.58±1.28）dinthecontrolgroup，andthedifferencewasstatisticallysignificant（p0.05）.thetreatmentgrouphadsignificantlyhighertotaleffectiverateas95.00%andantigennegativerateas86.67%than68.33%and48.33%inthecontrolgroup，andtheirdifferencewasstatisticallysignificant（p0.05）.therewasnosignificantadversereactionsoccurredintwogroups.conclusionrecombinanthumaninterferonα-1binthetreatmentofrotavirusenteritiscansignificantlyshortenthecourseoftreatment，rapidlyimprovesymptomswithnoobviousadversereactions.soitisworthyofclinicalpromotionandapplication. 　　【keywords】interferonα-1b;rotavirus;enteritis;bifidobacteriumtriplelivebacteria;montmorillonitepowder 　　轮状病毒性肠炎是婴幼儿秋冬季节的常见病，具有传染性和流行性，好发于6个月～3岁的婴幼儿，病原多为轮状病毒，该病常合并脱水、酸中毒和电解质紊乱，严重威胁小儿的生命健康。目前，对轮状病毒缺乏有效的治疗，为探讨有效的治疗方法，近